Search by Drug Name or NDC

NDC 00071-2418-19 Zarontin 250 mg/5mL Details

Zarontin 250 mg/5mL

Zarontin is a ORAL SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Parke-Davis Div of Pfizer Inc. The primary component is ETHOSUXIMIDE.

MedlinePlus Drug Summary

Ethosuximide is used to control absence seizures (petit mal) (a type of seizure in which there is a very short loss of awareness during which the person may stare straight ahead or blink his eyes and does not respond to others). Ethosuximide is in a class of medications called anticonvulsants. It works by reducing abnormal electrical activity in the brain.

Related Packages: 00071-2418-19
Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Ethosuximide

Product Information

NDC	00071-2418
Product ID	0071-2418_6afa95d3-162a-4fbb-ab47-561f4ee7771a
Associated GPIs	72400010002005
GCN Sequence Number	004555
GCN Sequence Number Description	ethosuximide SOLUTION 250 MG/5ML ORAL
HIC3	H4B
HIC3 Description	ANTICONVULSANTS
GCN	17430
HICL Sequence Number	001891
HICL Sequence Number Description	ETHOSUXIMIDE
Brand/Generic	Brand
Proprietary Name	Zarontin
Proprietary Name Suffix	n/a
Non-Proprietary Name	Ethosuximide
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	SOLUTION
Route	ORAL
Active Ingredient Strength	250
Active Ingredient Units	mg/5mL
Substance Name	ETHOSUXIMIDE
Labeler Name	Parke-Davis Div of Pfizer Inc
Pharmaceutical Class	Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE]
DEA Schedule	n/a
Marketing Category	ANDA
Application Number	ANDA080258
Listing Certified Through	2024-12-31

Package

NDC 00071-2418-19 (00071241819)

Pricing Information	N/A
NDC Package Code	0071-2418-19
Billing NDC	00071241819
Package	1 BOTTLE, PLASTIC in 1 CARTON (0071-2418-19) / 474 mL in 1 BOTTLE, PLASTIC
Marketing Start Date	2022-06-01
NDC Exclude Flag	N